Trial · NCT02979899

Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma

NCT02979899, Phase 3, Completed, Tracon Pharmaceuticals Inc.; results first posted 2020-05-12

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma. Trials, record NCT02979899. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02979899

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma
NCT number: NCT02979899
Status: Completed
Phases: Phase 3
Enrollment: 128 participants, actual
Lead sponsor: Tracon Pharmaceuticals Inc.
Conditions: Advanced Angiosarcoma
Interventions: TRC105, Votrient
First posted: 2016-12-02
Last updated: 2020-05-12
Results first posted: 2020-05-12

Source ClinicalTrials.gov

Registered outcomes4

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Progression Free Survival of Patients With Unresectable Angiosarcoma	from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to cut off date of interim analysis (25 months)	Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Progression free survival is defined as time from randomization to either first disease progression (per independent radiology review of images by RECIST 1.1) or death from any cause.
Secondary	Objective Response Rate of Patients With Unresectable Angiosarcoma	from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to cut off date of interim analysis (25 months)	Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions: Complete Response (CR) is disappearance of all target lesions; Partial Response (PR) is \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Overall response rate is defined as the number of patients with a best response designation of complete response or partial response recorded between the date of randomization and the date of documented progression.
Secondary	Overall Survival of Patients With Unresectable Angiosarcoma	from beginning of study to cut off date of interim analysis (25 months)	Overall survival is the number of death events at 25 months, including all on-study and off-study deaths (past post-treatment 28-day follow up visit)
Secondary	To Characterize Patient Reported Outcomes Between the Two Arms of the Study	Screening and 9 weeks (Cycle 3 Day 1)	Patient reported outcomes as measured by the EuroQol five dimensions questionnaire (EQ-5D-5L) and the European Organisation for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30). The EORTC QLQ-C30 health scale is on a scale of 1 to 7, with 1 being poor health and 7 being excellent health. The EQ-5D-5L scale is on a scale of 0 to 100, with 0 being the worst health one can imagine, and 100 being the best health one can imagine.

Source ClinicalTrials.gov

Outcomes4

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Progression Free Survival of Patients With Unresectable Angiosarcoma	from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to cut off date of interim analysis (25 months)	All patients randomized onto study by cut off date of interim analysis	months	MEAN
SECONDARY	Objective Response Rate of Patients With Unresectable Angiosarcoma	from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to cut off date of interim analysis (25 months)	All patients randomized onto study by cut off date of interim analysis	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Overall Survival of Patients With Unresectable Angiosarcoma	from beginning of study to cut off date of interim analysis (25 months)	All patients randomized onto study by cut off date of interim analysis	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	To Characterize Patient Reported Outcomes Between the Two Arms of the Study	Screening and 9 weeks (Cycle 3 Day 1)	All patients who completed the questionnaire during specified intervals listed below	units on a scale	MEDIAN

Source ClinicalTrials.gov

Results by group16

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Progression Free Survival of Patients With Unresectable Angiosarcoma	TRC105 + Votrient	PFS by RECIST 1.1	4.2	95% Confidence Interval 2.8 to 8.3	months
Progression Free Survival of Patients With Unresectable Angiosarcoma	Votrient	PFS by RECIST 1.1	4.3	95% Confidence Interval 2.9 to NA	months
Progression Free Survival of Patients With Unresectable Angiosarcoma	TRC105 + Votrient	PFS by Investigator Assessment	3.5	95% Confidence Interval 2.6 to 5.5	months
Progression Free Survival of Patients With Unresectable Angiosarcoma	Votrient	PFS by Investigator Assessment	2.9	95% Confidence Interval 2.6 to 4.1	months
Objective Response Rate of Patients With Unresectable Angiosarcoma	TRC105 + Votrient		3		Participants
Objective Response Rate of Patients With Unresectable Angiosarcoma	Votrient		8		Participants
Overall Survival of Patients With Unresectable Angiosarcoma	TRC105 + Votrient		17		Participants
Overall Survival of Patients With Unresectable Angiosarcoma	Votrient		19		Participants
To Characterize Patient Reported Outcomes Between the Two Arms of the Study	TRC105 + Votrient	EORTC QLQ-C30 Health Score at Screening	5	Full Range 1 to 7	units on a scale
To Characterize Patient Reported Outcomes Between the Two Arms of the Study	Votrient	EORTC QLQ-C30 Health Score at Screening	5	Full Range 1 to 7	units on a scale

1 to 10 of 16Source ClinicalTrials.gov

See all 16 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	TRC105 + Votrient	64
Overall Study	STARTED	Votrient	64
Overall Study	COMPLETED	TRC105 + Votrient	64
Overall Study	COMPLETED	Votrient	64
Overall Study	NOT COMPLETED	TRC105 + Votrient	0
Overall Study	NOT COMPLETED	Votrient	0

Source ClinicalTrials.gov

Adverse events314

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Fatigue	General disorders	TRC105 + Votrient	42	63
other	Fatigue	General disorders	Votrient	33	57
other	Diarrhea	Gastrointestinal disorders	TRC105 + Votrient	38	63
other	Diarrhea	Gastrointestinal disorders	Votrient	31	57
other	Nausea	Gastrointestinal disorders	TRC105 + Votrient	34	63
other	Nausea	Gastrointestinal disorders	Votrient	26	57
other	Hypertension	Vascular disorders	TRC105 + Votrient	24	63
other	Hypertension	Vascular disorders	Votrient	32	57
other	Headache	Nervous system disorders	TRC105 + Votrient	42	63
other	Headache	Nervous system disorders	Votrient	14	57

1 to 10 of 314Source ClinicalTrials.gov

See all 314 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	TRC105 + Votrient	23	64
Total, all-cause mortality	Votrient	20	64
Total, other adverse events	TRC105 + Votrient	63	63
Total, other adverse events	Votrient	57	57
Total, serious adverse events	TRC105 + Votrient	27	63
Total, serious adverse events	Votrient	12	57

Source ClinicalTrials.gov

Papers2

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
30357394	DERIVED	PubMed
35357396	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons4

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
TRC105 + Votrient vs Votrient: Objective Response Rate of Patients With Unresectable Angiosarcoma	Trial comparisons
TRC105 + Votrient vs Votrient: Overall Survival of Patients With Unresectable Angiosarcoma	Trial comparisons
TRC105 + Votrient vs Votrient: deaths from any cause	Trial comparisons
TRC105 + Votrient vs Votrient: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02979899

GET https://conductscience.org/api/trials/v1/NCT02979899/events?page=2

API reference For AI assistants